Companies › pharmaand
1 active drug program in 5 registered trials: 3 Phase 2, 1 Phase 3, 1 Phase 1; Oncology; next expected readout Dec 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rucaparib PARP 1, 2 and 3 inhibitor | PARP1, PARP3, PARP2 | Phase 3 | Epithelial Ovarian Cancer; Leiomyosarcoma; Peritoneal Cancer; Adenocarcinoma of the Oesophagus … | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04624178 | Rucaparib | Phase 2 | Leiomyosarcoma | Oncology | Nov 2026 |
| NCT02873962 | Rucaparib | Phase 2 | Peritoneal Cancer | Oncology | Jan 2027 |
| NCT04253262 | Rucaparib | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Jan 2027 |
| NCT02678182 | Rucaparib | Phase 2 | Adenocarcinoma of the Oesophagus | Oncology | Jun 2027 |
| NCT03522246 | Rucaparib | Phase 3 | Epithelial Ovarian Cancer | Oncology | Dec 2030 |
AstraZeneca Merck & Co. (MSD) Boryung Pharmaceutical Daewoong Pharmaceutical Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene Impact Therapeutics
Maia Biotechnology K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) Epizyme CanariaBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.